ClinicalTrials.gg
CompletedNCT05757570Updated Sep 14, 2026

An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4)

A Phase 1/2 interventional study of Povetacicept in Idiopathic Thrombocytopenic Purpura, Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia, sponsored by Alpine Immune Sciences Inc, A Subsidiary of Vertex. Completed at 44 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by Alpine Immune Sciences Inc, A Subsidiary of Vertex (part of Vertex Pharmaceuticals Incorporated) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United States — 18 open to participants now, 22 under way, 9 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · United States.

Enrollment
59th of 94
30 · median 42
Started
2023
with 5 others
Phase 1/2
10 of 110
3 open now
Registered
89th of 110
by date

Among the 110 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United States, this one is the 59th largest by enrollment of the 94 interventional ones that give a count, is one of 6 that started in 2023, is one of 10 in phase 1/2, and was the 89th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

18 of the 110 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical study is to evaluate povetacicept in adults with autoimmune cytopenias of immune thrombocytopenia, autoimmune hemolytic anemia, and cold agglutinin disease to determine if povetacicept is safe and potentially beneficial in treating these diseases. During the study treatment period participants will receive povetacicept approximately every 4 weeks for 6 months, with the possibility of participating in a 6-month study treatment extension period.

03

Conditions studied

  • Idiopathic Thrombocytopenic Purpura
  • Immune Thrombocytopenia
  • Warm Autoimmune Hemolytic Anemia
  • Cold Agglutinin Disease

Keywords

  • Immune Thrombocytopenia
  • Warm Autoimmune Hemolytic Anemia
  • Cold Agglutinin Disease
  • Autoimmune Cytopenia
  • Idiopathic Thrombocytopenic Purpura
  • Immune Thrombocytopenic Purpura
  • Hemolytic Anemia
  • RUBY4
  • RUBY-4
  • Povetacicept
  • ALPN-303
  • ALPN303
  • Autoimmune Hemolytic Anemia
  • ITP
  • wAIHA
  • AIHA
  • CAD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Indication-specific Criteria

    1. Immune Thrombocytopenia (ITP)

      • Documented persistent or chronic primary ITP of at least 12 weeks duration from diagnosis to Cycle 1 Day 1
      • History of failure or relapse to at least 2 treatment regimens for ITP
      • History of exposure to a TPO-RA unless otherwise or unavailable
      • Documented history of \<30 × 10\^9/L
    2. Warm Hemolytic Anemia (wAIHA)

      • Diagnosis of primary wAIHA of at least 12 weeks duration documented with a current or prior positive direct antiglobulin test (DAT) for anti-IgG (±C3d)
      • Documented history of anemia with ≤10 g/dL
      • At least one of the following: (i) haptoglobin \< lower limit of normal (LLN) (ii) indirect > (ULN) (iii) lactate dehydrogenase>ULN
      • History of failure or relapse to at least 2 treatment regimens for wAIHA
    3. Cold Agglutinin Disease (CAD)

      • Diagnosis of primary CAD of at least 12 weeks duration with all of the following: (i) chronic hemolysis (ii) polyspecific DAT positive (iii) monospecific DAT strongly positive for C3d (iv) cold agglutinin titer ≥64 at 4°C (v) IgG DAT ≤1+ (vi) no overt malignant disease
      • Documented history of anemia with hemoglobin ≤10 g/dL
      • Evidence of hemolysis during screening: (i) indirect bilirubin

        >ULN and (ii) lactate dehydrogenase>ULN or haptoglobin \<LLN

      • History of failure or relapse to at least 1 treatment regimen for CAD
  2. (All indications) If receiving protocol-specified standard-of-care medications, doses must be stable for protocol-specified durations

Key Exclusion Criteria:

  1. Secondary AIHA, CAD, or ITP
  2. Treatment with any of the following within the noted period prior to study entry

    1. rituximab: \<12 weeks
    2. IVIg: \<4 weeks
    3. sutimlimab, any use after initiation of screening is exclusionary
    4. plasmapheresis, plasma exchange, or double-filtration plasmapheresis: \<8 weeks
    5. transfusions with blood, blood products or other rescue medications: \<2 weeks
    6. splenectomy: \<12 weeks
    7. other immunomodulatory or agents, except for investigational agents for COVID-19 that have been granted emergency use authorization or approved by the applicable national health authority: \<5 half-lives and requires agreement of the Medical Monitor
  3. Recent serious or ongoing infection; risk or history of serious infection Other protocol defined Inclusion/Exclusion criteria may apply.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Part 1: Povetacicept 240mg

    Participants grouped in 3 cohorts by diagnosis will be administered Povetacicept.

    Drug: Povetacicept

  • Experimental
    Part 2: Povetacicept Dose A

    Based on the findings of Part 1, one or two dose levels may be assessed in Part 2; if two dose levels are assessed participants will be randomized to receive one of the two dose levels of Povetacicept.

    Drug: Povetacicept

Interventions

  • Administered by subcutaneous injection every 4 weeks

    Also known as: ALPN-303

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability as Assessed by Adverse events (AEs) and Serious adverse events (SAEs)

    Time frame: Study Day 1 through 30 days after last dose of study drug

07

Study locations

44 sites
  • Investigational Site (230)
    Los Angeles, California 90033, United States
  • Investigational Site (401)
    Washington D.C., District of Columbia 20007, United States
  • Investigational Site (419)
    Cooper City, Florida 33024, United States
  • Investigational Site (425)
    Miami, Florida 33143, United States
  • Investigational Site (219)
    Iowa City, Iowa 52242, United States
  • Investigational Site (435)
    Columbia, Maryland 21044, United States
  • Investigational site (405)
    Lake Success, New York 11042, United States
  • Investigational Site (423)
    New Hyde Park, New York 11040, United States
  • Investigational Site (421)
    New York, New York 10028, United States
  • Investigational Site (404)
    New York, New York 10065, United States
  • Investigational Site (420)
    Shirley, New York 11967, United States
  • Investigational Site (422)
    The Bronx, New York 10469, United States
  • Investigational Site (414)
    Charlotte, North Carolina 28204, United States
  • Investigational Site (402)
    Greenville, North Carolina 27834, United States
  • Investigational Site (411)
    Seattle, Washington 98109, United States
  • Investigational Site (410)
    Box Hill, 3128, Australia
  • Investigational Site (519)
    Concord, 2139, Australia
  • Investigational Site (517)
    Douglas, 4814, Australia
  • Investigational Site (413)
    Liverpool, 2170, Australia
  • Investigational Site (407)
    West Perth, 6005, Australia
  • Investigational Site (409)
    Westmead, 2145, Australia
  • Investigational Site (434)
    Vienna, 1090, Austria
  • Investigational Site (406)
    Greenfield Park, J4V2H1, Canada
  • Investigational Site (403)
    Hamilton, L8S 4K1, Canada
  • Investigational Site (444)
    Toronto, M5B 1W8, Canada
  • Investigational Site (438)
    Essen, 45147, Germany
  • Investigational Site (432)
    Meldola, 47014, Italy
  • Investigational Site (428)
    Milan, 20122, Italy
  • Investigational Site (431)
    Novara, 28100, Italy
  • Investigational Site (443)
    Trieste, 34128, Italy
  • Investigational Site (433)
    Grålum, 1714, Norway
  • Investigational Site (437)
    Trondheim, 7030, Norway
  • Investigational Site (436)
    Barcelona, 08003, Spain
  • Investigational Site (429)
    Burgos, 9006, Spain
  • Investigational Site (430)
    Madrid, 28007, Spain
  • Investigational Site (426)
    Murcia, 30008, Spain
  • Investigational Site (427)
    Seville, 41013, Spain
  • Investigational Site (415)
    Ankara, 06200, Turkey (Türkiye)
  • Investigational Site (416)
    Ankara, 06800, Turkey (Türkiye)
  • Investigational Site (418)
    Istanbul, 34718, Turkey (Türkiye)
  • Investigational Site (442)
    Leeds, SE1 9RT, United Kingdom
  • Investigational Site (439)
    London, E1 1BB, United Kingdom
  • Investigational Site (441)
    London, SE1 9RT, United Kingdom
  • Investigational Site (440)
    London, W12 0HS, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in Aug 2026, 37 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2023
First posted
Mar 7, 2023
StartActual
Jul 3, 2023
Primary completionActual
Aug 12, 2026
CompletionActual
Aug 12, 2026
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05757570
Responsible party
Sponsor
First posted
Mar 7, 2023
Start date
Jul 3, 2023
Primary completion
Aug 12, 2026
Completion
Aug 12, 2026
Last update
Sep 14, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Povetacicept

Start the discussion